Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097460 | 0.86 | ALDH1A1 (0.46) | PIK3CAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL29740650 | 0.83 | PIK3CD (0.49) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL20124865 | 0.83 | PIK3CD (0.49) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL20502398 | 0.81 | ALDH1A1 (0.48) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL2940366 | 0.81 | MAP4K1 (0.50) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL1438679 | 0.81 | PIK3CD (0.46) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL10272402 | 0.81 | ALDH1A1 (0.52) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL17202841 | 0.81 | ALDH1A1 (0.65) | F10MEN1KMT2ANPC1RAB9A | |
| SCHEMBL670900 | 0.81 | MAP4K1 (0.50) | F10PTGS2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL19086541 | 0.80 | PTGS2 (0.64) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | F10 1624/4885PTGS2 678/4885PIK3CD 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.